Transcend is developing one of the most promising psychoactive compounds – with previous human experience to treat PTSD NEW YORK, Feb. 23, 2023 /PRNewswire/ — Transcend Therapeutics, a biotechnology company that develops medicines to treat neuropsychiatric diseases, including post-traumatic stress disorder (PTSD), today announced that it closed its Series A funding round of $40 million.


Previous articleIsrael-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
Next articlePanel: Psychedelic Careers